Tamsulosin
- Generic Name
- Tamsulosin
- Brand Names
- Flomax, Jalyn
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5S
- CAS Number
- 106133-20-4
- Unique Ingredient Identifier
- G3P28OML5I
- Background
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor mus...
- Indication
Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus
- Associated Therapies
- -
Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1060
- Registration Number
- NCT02245555
Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients
- Conditions
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 403
- Registration Number
- NCT02244229
Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin
- Conditions
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 30
- Registration Number
- NCT02239484
- Locations
- 🇰🇷
Samgsung Seoul Hospital, Seoul, Korea, Republic of
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
- Conditions
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02180997
- Locations
- 🇰🇷
Seoul National University Hospital(SNUH), Seoul, Jongno-Gu, Korea, Republic of
Ureteral Stent-related Pain and Mirabegron (SPAM) Trial
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 22
- Registration Number
- NCT02095665
- Locations
- 🇨🇦
Nova Scotia Health Authority, Central, Halifax, Nova Scotia, Canada
A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 320
- Registration Number
- NCT02038868
The Effect of Daily Tamsulosin 0.2mg Administration on Renal Function in Patients With Benign Prostatic Hyperplasia
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 34
- Registration Number
- NCT02033798
- Locations
- 🇰🇷
St. Vincent's Hospital, Suwon, Gyeonggi-do, Korea, Republic of
Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 194
- Registration Number
- NCT02034604
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 104
- Registration Number
- NCT02003742
- Locations
- 🇩🇪
Klinikum der Ludwig-Maximilians-universität München, Munich, Germany
🇮🇹Vita e Salute University, Department of Urology, Istituto Scientifico Ospedale San Raffaele, Milan, Italy
🇵🇱Niepubliczny Zaklad Opieki Zdrowotnej Specjalista, Kutno, Poland
A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin
- Conditions
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 30
- Registration Number
- NCT01953887
- Locations
- 🇬🇧
Parexel, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.